Clinical Trials Logo

Non-small Cell Lung Cancers clinical trials

View clinical trials related to Non-small Cell Lung Cancers.

Filter by:
  • None
  • Page 1

NCT ID: NCT06130254 Recruiting - Clinical trials for Advanced Solid Tumor

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Start date: January 30, 2024
Phase: Phase 1
Study type: Interventional

Evaluate safety and tolerability, while establishing the recommended dose of the investigational drug combination of adagrasib and olaparib that can be given to participants with advanced solid tumor(s) with a KRAS G12C and/or KEAP1 mutation.

NCT ID: NCT05639751 Recruiting - Clinical trials for Advanced Solid Tumor

PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation

Start date: May 2, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1 dose-escalation study of PRT3789, a SMARCA2 degrader, in participants with advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of PRT3789 monotherapy and in combination with docetaxel, describe any dose limiting toxicities (DLTs), define the dosing schedule, and to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) to be used in subsequent development of PRT3789.

NCT ID: NCT05538572 Active, not recruiting - Breast Cancer Clinical Trials

A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors

Start date: December 27, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1 dose-escalation study of PRT3645, a Cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor, in patients with advanced or metastatic solid tumors. The purpose of this study is to investigate the safety, tolerability, dose limiting toxicity, and to determine maximally tolerated dose and recommended phase 2 dose to be used in subsequent development of PRT3645.

NCT ID: NCT01871454 Recruiting - Clinical trials for Non-small Cell Lung Cancers

Safety of Pentoxifylline and Vitamin E With Stereotactic Ablative Radiotherapy (SABR) in Non-small Cell Lung Cancers

Start date: October 2013
Phase: Phase 2
Study type: Interventional

The objective of this prospective phase II protocol is to assess the toxicity and efficacy of pentoxifylline and SABR in the re-treatment of recurrent or new lung cancers